Best AI Neurology Tools

RapidAI earns the top spot on evidence. Its perfusion software, which maps how much brain tissue is dead and how much can still be saved, was used to select patients in DEFUSE 3, the randomised trial that extended the thrombectomy window to 16 hours. That work fed directly into stroke guidelines, and RapidAI says its perfusion analysis is the only one validated in randomised trials.

The platform now covers much more than perfusion: large and medium vessel occlusion detection, non-contrast CT, haemorrhage, midline shift and aortic imaging. In November 2025 it added five FDA clearances at once, and Lumina 3D creates instant 3D views of head and neck CT angiograms. RapidAI has 20 entries on the FDA AI list and says it runs in more than 2,500 hospitals in over 100 countries.

Its care-coordination app is solid but less central to its identity than Viz.ai's.

Pick it if your stroke programme depends on advanced imaging to decide who gets thrombectomy. Skip it if your main pain point is team communication rather than image analysis.

Viz.ai invented the category. In February 2018 the FDA granted it the first De Novo authorisation for AI software that alerts a specialist to a suspected large vessel occlusion stroke. Its real strength is what happens next: the Viz app puts the scan, the alert and a secure team chat on every stroke team member's phone, so a neurointerventionalist at home can see images and accept a transfer within minutes.

The platform has grown to 50+ 510(k) clearances across stroke, brain bleeds, aneurysms and subdural haematoma, plus cardiology, pulmonary embolism and aortic disease. Viz.ai says it is deployed at 1,800 hospitals.

The evidence base is large but mostly observational: many single- and multi-centre studies report faster treatment times after adoption, but there is no randomised trial of the software itself. That is why RapidAI edges it on evidence.

Pick it if you run a hub-and-spoke stroke network where communication delays cost the most time. Skip it if you mainly need advanced perfusion analysis.

Ceribell solves a practical problem: conventional EEG needs a technician to glue on electrodes and a specialist to read it, which many hospitals cannot provide at 2am. Ceribell uses a headband that a nurse can put on in minutes, and its Clarity AI watches the signal continuously and flags seizures.

Its regulatory record is the strongest in EEG AI. Clarity is cleared for patients of all ages, including pre-term newborns since November 2025. ClarityPro is cleared to diagnose electrographic status epilepticus (a prolonged seizure that is a medical emergency) in adults, and CMS pays hospitals an add-on of up to $913.90 per eligible Medicare case. A delirium monitoring tool was cleared in December 2025, and a stroke detection tool has Breakthrough Device designation.

The limits are scope and cost structure. It uses fewer electrodes than a full EEG, so it complements rather than replaces formal EEG, and hospitals commit to hardware and disposables.

Pick it if your ICU or emergency department has limited EEG access. Skip it if you already run 24/7 full EEG monitoring with in-house readers.

Brainomix has the most convincing real-world outcome data in stroke AI. A study published in The Lancet Digital Health in December 2025 tracked more than 450,000 admissions across 107 NHS England hospitals, including over 71,000 ischaemic stroke patients before and after AI roll-out. Thrombectomy rates doubled at the 26 hospitals using Brainomix 360, against a 63% rise elsewhere, and transfer times at primary stroke centres fell by 64 minutes. It is observational, and Brainomix staff co-authored it alongside the NHS national clinical director for stroke, but the scale is unmatched.

In the US its footprint is smaller. The FDA has cleared its e-ASPECTS scoring and, in 2025, a feature that estimates the stroke core from ordinary non-contrast CT, which helps hospitals without perfusion imaging.

Pick it if you run a regional stroke network, particularly in the UK or Europe, and want proven impact on treatment rates. Skip it if you need the broadest US-cleared menu; RapidAI and Viz.ai have more.

Persyst is the long-standing standard for EEG review software. Its algorithms mark likely seizures and spikes in long recordings and turn hours of brain waves into trend charts a neurologist can scan in minutes. Most large EEG vendors support it, and it is often the software neurophysiologists trained on.

The regulatory position is strong. Persyst 15 includes FDA-cleared seizure detection for adults and an electrographic status epilepticus component that can support a diagnosis in adults, and the FDA cleared a newer version (K252160) in October 2025. In December 2025 Natus won clearance for its BrainWatch point-of-care EEG with Persyst built in, which makes Persyst a direct rival to Ceribell at the bedside.

It is software for experts. It needs a full EEG setup and trained readers, and its seizure detection clearance covers adults rather than all ages.

Pick it if you run an EEG lab or epilepsy monitoring unit. Skip it if you need a nurse-applied system for units without EEG staff; look at Ceribell.

NeuroQuant is one of the longest-used brain MRI measurement tools. It segments the brain into regions and compares volumes, such as the hippocampus, with age-matched norms, which helps with dementia, epilepsy and brain injury work-ups.

Its relevance has grown with anti-amyloid Alzheimer's drugs, which require repeated MRI checks for ARIA, a side effect that shows up as brain swelling (ARIA-E) or small bleeds (ARIA-H). NeuroQuant 5.0, cleared in September 2024, helps radiologists segment and quantify these changes. In August 2026 the FDA cleared NeuroQuant PET (K261916), which reports amyloid PET results as standardised uptake ratios and Centiloids for three common tracers. That lets one vendor cover both the MRI and PET parts of an Alzheimer's treatment pathway.

Most of its accuracy data comes from validation studies rather than outcome trials, which is typical for measurement tools.

Pick it if you run a memory clinic or radiology service supporting anti-amyloid treatment. Skip it if you mainly need MS lesion tracking; icobrain is stronger there.

icometrix, a Belgian company, makes icobrain, a family of MRI tools for multiple sclerosis, dementia and brain injury. Its standout product is icobrain aria, which the FDA cleared in November 2024 as the first AI software to detect, measure and grade ARIA, the brain swelling and micro-bleeds that anti-amyloid Alzheimer's drugs can cause. The company reports that radiologists using it were 16% more sensitive for ARIA-E and 10% more sensitive for ARIA-H; that comes from a company-backed reader study.

Its MS module tracks new and enlarging lesions and brain volume loss over time, which helps neurologists judge whether a treatment is working.

icobrain and NeuroQuant overlap heavily, and the choice often comes down to which PACS integration and reports your radiologists prefer. We place icobrain just behind because NeuroQuant now also covers amyloid PET.

Pick it if you manage many MS patients or run an anti-amyloid infusion programme. Skip it if you need PET quantification from the same vendor.

Combinostics, a Finnish company, builds cNeuro, a dementia-focused platform. cNeuro cMRI measures atrophy in brain regions and white matter changes, and cNeuro cPET, cleared by the FDA in September 2023, quantifies PET scans. In Europe it also offers cDSI, a disease state index that compares a patient's data with large reference cohorts to suggest which type of dementia is most likely. That decision-support part is CE-marked but not FDA-cleared, so US users get the measurement tools only.

Its approach grew out of European dementia research projects, and it is well suited to memory clinics that combine MRI, PET and cognitive tests. In the US it is a smaller player than NeuroQuant or icobrain, and we found no recent outcome studies.

Pick it if you run a European memory clinic and want decision support across several tests. Skip it if you are in the US and need ARIA monitoring; its competitors have specific clearances for that.

Methinks, a Barcelona-based start-up, focuses on a real gap: many small and rural hospitals only do a plain (non-contrast) CT scan when a stroke patient arrives, and most LVO algorithms need a CT angiogram. In July 2025 the FDA cleared Methinks NCCT Stroke to flag suspected large vessel occlusions from non-contrast CT alone, and a second 2025 clearance covers CTA, including more distal M2 occlusions.

The company says its non-contrast tool cuts false negatives by nearly half compared with the best competing product, and reports 98.2% sensitivity and 91.6% specificity for its CTA tool. These are figures from its regulatory validation, and we found little independent published data yet.

It is a narrower and younger product than RapidAI or Viz.ai, without their care-coordination depth.

Pick it if you run a spoke hospital without routine CTA and want earlier transfer decisions. Skip it if you need a full stroke platform.

encevis is EEG analysis software from the Austrian Institute of Technology. Like Persyst, it scans long EEG recordings for seizures and for rhythmic and periodic patterns common in intensive care, and shows trends that speed up review. It is CE-marked and has been used mostly in European epilepsy and ICU settings.

The FDA cleared it in September 2024 (K240993), so it is now an option for US labs. Independent comparisons of commercial seizure detectors, including encevis and Persyst, have been published, and a 2025 paper compared versions of these tools, which is healthy for a field that relies mostly on vendor validation.

Its US presence and integration list are smaller than Persyst's, and it has no point-of-care hardware partner comparable to Natus or Ceribell.

Pick it if you run a European EEG lab or want a second-opinion detector. Skip it if you need the most widely supported tool in US EEG systems.